6533b7d6fe1ef96bd126703e
RESEARCH PRODUCT
Diabetes and COVID-19: What 2 Years of the Pandemic Has Taught Us
Anca Pantea StoianPeter KemplerThomas StulnigAli A. RizviManfredi Rizzosubject
GlucoseCOVID-19 cardiometabolic risk complications diabetes obesity treatmentSARS-CoV-2Endocrinology Diabetes and MetabolismDiabetes MellitusInternal MedicineCOVID-19HumansPandemicsdescription
As the world enters its third year of the COVID-19 pandemic, individuals with diabetes have faced particular challenges from the virus. A deleterious bidirectional relationship exists between the two disorders, with heightened inflammatory, immunologic, and cellular mechanisms leading to a more severe illness and increased morbidity and mortality. Tight glucose control, though necessary, is hampered by physical restrictions and difficulty accessing health care. Novel glucose-lowering medications may provide unique benefits in this regard. It is imperative that multi-pronged efforts be prioritized in order to reduce adverse outcomes in patients with diabetes at risk for COVID-19.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2022-04-01 | Metabolic Syndrome and Related Disorders |